Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone ophthalmic - Allergan

Drug Profile

Dexamethasone ophthalmic - Allergan

Alternative Names: DEX implant; DEX PS DDS; Dexamethasone implant; Dexamethasone posterior segment drug delivery system; Ozurdex; Posurdex; SK-0503

Latest Information Update: 15 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer Allergan; Johns Hopkins University; Sanwa Kagaku Kenkyusho
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Non-opioid analgesics; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema; Retinal oedema; Uveitis
  • Phase II/III Retinal vein occlusion
  • No development reported Age-related macular degeneration

Most Recent Events

  • 22 Mar 2018 Launched for Retinal oedema in China (Intravitreous)
  • 30 Oct 2017 Registered for Retinal oedema in China (Intravitreous)
  • 05 Jun 2017 Jaeb Center for Health Research, in collaboration with Allergan and Genentech, completes a phase II trial in Diabetic macular oedema (Combination therapy) in USA (Intravitreous) (NCT01945866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top